untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.
Introduction
Assessment of estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression is a central part of the pathological work-up for breast cancer (BC) patients. ER, PgR, and HER2 expression allows patients allocation in three main groups: (i) ER/PgR positive (estrogen-driven ED tumors) accounting for 75-80 % of BC, who will receive endocrine treatment; (ii) HER2 positive (HER2-driven tumors) accounting for 15-20 % of BC, who will receive HER2 target therapy such as trastuzumab or lapatinib and (iii) a group accounting for 10-15 % of BC not expressing either ER/PgR or HER2 (the so-called ''triplenegative tumors'' TN) for whom no target therapy is available and chemotherapy remains the systemic treatment of choice.
Gene expression studies using DNA microarrays have identified at least five molecular subclasses of BC with distinct features: luminal A and B (ER?/PgR?/HER2-), HER2 overexpressing (ER-/PgR-/HER2?), basal-like (ER-/PgR-/HER2-and basal cytokeratins?), and normal-like BC [1, 2] . The TN and the basal-like subgroups share common features (i.e., lack of ER, PgR, and HER2 expression) and, consequently, have been often referred as synonymous [3, 4] . Although there is extensive overlap between the TN and basal-like BC, it is not complete. Basal-like BC is a more homogeneous group of tumors, while TN group can comprise also other subtypes of BC with distinct biologic features [5] [6] [7] . Recently an IHC surrogate to define basal cancers has been suggested by Nielsen et al. [8] using ER, PgR, HER2, EGFR, and cytokeratins (CK) 5/6. Despite this, patients are routinely assessed as TN exclusively on the basis of ER, PgR, and HER2 determination. Numerous studies have shown that TN tumors and basal-like tumors display features of tumor aggressiveness and poor outcome compared to other subtypes [9] . However, most of these studies rely either on limited cohorts of patients or are derived from patient populations treated with chemotherapy and/or endocrine therapy and therefore cannot derive pure prognostic information.
We sought to determine the clinical and biologic features of TN and ED BC in a well-characterized cohort of BC patients comprising a large group of systemically untreated patients. Full information about ER/PgR and HER2 status along with other biological characteristics were available.
Methods

Patient data and specimens
The Lester and Sue Smith Breast Center at Baylor College of Medicine maintains a database of BC patients whose tissue specimens were originally sent to a central reference laboratory for steroid receptor assays at the Nichols Institute in California. Follow-up information and pathologic characteristics were obtained from tumor registries, medical records, or by data collection forms completed by the referring physicians. This database contains information on 47,286 patients diagnosed between 1984 and 1999 with early breast cancer (stage I-IIIA). This repository has been reviewed by Institutional Review Boards at the University of Texas Health Science Center at San Antonio and at Baylor College of Medicine and both boards provided a waiver of informed consent. No patient identifiers were provided to the authors.
Statistical methods
Of 2,567 patients with complete ER and PgR information in our database, 2,200 had complete data on ER, PgR, and HER2. Among those, 253 were TN (ER/PgR/HER2 negative) and 1,036 were ED (ER/PgR?HER2 negative).
One thousand two-hundred seventy-eight subjects in the data set did not fall into one of these categories ( Table 1) .
The patient and tumor characteristics were summarized for 1,289 patients with TN and ED tumors, and the relationships between these characteristics and TN or ED status were examined using descriptive statistics and the Chisquared test (Table 2) . Next, the variables of interest were compared in TN patients by EGFR, ploidy status and S-phase status using descriptive statistics and the Chisquared test.
Time to first recurrence (TTFR) was calculated from the diagnostic biopsy date and a first recurrence was scored as an event while patients without an event were censored at the time of death or last follow-up. Overall survival (OS) was calculated from the diagnostic biopsy date and death was scored as an event whereas patients who were alive at the time of last follow-up were censored.
The effects of ED versus TN status on TTFR and OS were examined using Kaplan-Meier curves, and differences in survival were evaluated with the log-rank test in all subjects and by treatment status. In addition, timevarying covariates were employed to test the proportional hazards assumption of ED versus TN status in the survival analysis. Univariable Cox regression was also used to model the effects of EGFR status, ploidy and S-phase on TTFR and OS in TN subjects, and hazard ratios with 95 % confidence intervals and p values were calculated for these models. Multivariable analysis assessed the simultaneous importance of ED versus TN status, tumor size, nodal status, and S-phase on OS and time to first recurrence in all subjects and by treatment group and among TN subjects by EGFR status ploidy status and S-phase Cox regression was used to model the relationships, and adjusted hazards ratios, 95 % confidence intervals (CI), and p values were calculated for the multivariable models. All analyses were performed using SAS 9.2 (SAS, Cary, NC). [12, 13] . Levels C3 fmol/mg protein were considered positive for ER and levels C5 fmol/mg protein were considered positive for PgR. DNA ploidy and S-phase fraction were evaluated by flow cytometry as previously described [14] [15] [16] . S-phase fractions \6 % were considered low, 6-10 % intermediate, and [10 % high. HER-2 status was determined by Western blotting [17] . The cut off value between low and high HER-2 expression was 1 U/lg protein.
EGFR levels were measured by radioligand binding assay, using fixed concentrations of radiolabeled epidermal growth factor (EGF) and varying concentrations of unlabeled EGF. Levels C10 fmol/mg were considered positive. This cutoff has been in use at the Nichols Institute since 1992 and is in agreement with the majority of published studies [18] .
Results
Demographic, clinical, biological characteristics
We identified 253 patients with TN and 1,036 patients with ED tumor. Table 2 summarizes the clinical and biological tumor characteristics according to tumor type.
Patients with TN BC were more likely to be younger (median age: 52 years in TN patients vs. 63 years in ED; p \ 0.0001), to be pre-menopausal (26.9 % of TN vs. 8.9 % of ED; p \ 0.0001) and African-American (12.4 % of TN vs. 4 % of ED; p \ 0.0001).
TN tumors were slightly larger on average (54.9 % larger than 2 cm) than ED tumors (46.6 % larger than 2 cm), (p = 0.0227). No difference in the frequency of axillary node involvement was observed.
Compared with ED tumors, TN tumors were much more likely to be aneuploid (64.4 % in TN vs. 42.7 % in ED; p \ 0.0001) and to have an higher proliferation rate (high S-phase fraction 53.9 % in TN vs. 16.8 % in ED; p \ 0.0001). Interestingly, positive EGFR expression was 6.5 times more likely to occur in TN tumors than in ED tumors (EGFR high expression: 49 % in TN and 7 % in ED tumors; p \ 0.0001).
Triple-negative phenotype and EGFR expression
Patients with TN BC (n = 253) could be further divided according to EGFR status with 124 women being EGFR-positive and 129 being EGFR-negative (Table 3) . Of note, among TN patients, women with EGFR-positive disease were younger and 2.5 times more likely pre-menopausal compared to patients with EGFR-negative BC. Median age was 47 years in patient with EGFR-positive and 61 years in patients with EGFR-negative disease, respectively (p \ 0.0001) and 40 % of women with EGFR-positive breast cancer were premenopausal compared to 16.7 % of patients with an EGFR-negative disease (p = 0.0007).
In addition, tumors expressing EGFR were larger (65.2 % EGFR-positive vs. 44.9 %; EGFR-negative tumor were larger than 2 cm; p = 0.0018), more likely to be aneuploid (78.9 % of EGFR-positive vs. 50 % of EGFR-negative tumor; p \ 0.0001) and displayed an higher proliferation rate (69.2 % EGFR-positive vs. 40.9 % EGFR-negative had high S-phase fraction; p \ 0.0001).
The vast majority (69.4 %) of patients with EGFR-positive disease received systemic adjuvant treatment compared to EGFR-negative patients (52.2 %) (p = 0.0014).
Triple-negative phenotype and ploidy status
Subjects with aneuploid TN tumor were more likely to be younger (median age was 50 years in aneuploid TN patients vs. 57 years in diploid TN patients; p = 0.04) and were slightly larger on average (64.1 % larger than 2 cm) than diploid TN tumors (37.4 % larger than 2 cm), (p \ 0.0001). Aneuploid TN BC was more likely to be invasive ductal carcinoma (IDC) (91.8 %) compared to diploid TN tumors (78.4 %) (p = 0.0009). No difference in race, menopausal status or in the frequency of axillary node involvement was observed.
Interestingly, compared with diploid-, aneuploid-TN tumors were much more likely to have an higher proliferation rate (79.2 % in aneuploid TN vs. 13.9 % of diploid TN tumors; p \ 0.0001). Moreover, aneuploid TN tumors more frequently expressed high levels of EGFR compared to diploid TN tumors (61.0 % in aneuploid vs. 29.6 % in diploid TN tumors; p \ 0.0001) ( Table 3) . Table 3) .
Clinical outcomes
Patients with TN BC were more frequently treated with adjuvant systemic therapy compared to patients with ED tumors. Indeed, 47.8 % of patients with ED breast cancer and 39.5 % of patients with TN disease did not receive any type of adjuvant systemic treatment (p \ 0.0001). Chemotherapy was the treatment of choice in patients with TN BC. Fiftythree percent of TN patients received adjuvant chemotherapy with or without endocrine therapy compared to 26.5 % of ED patients (p \ 0.0001). On the other hand, given the absence of ER/PgR, adjuvant endocrine therapy was given less frequently to patients with TN tumor (7.2 %), compared to patients with ED tumor (25.7 %) (p \ 0.0001) (Table 4) .
Overall, TN patients had a shorter time to first recurrence (TTFR) (OR, 0.503; 95 % CI, 0.371-0.682; p \ 0.0001) and OS (OR, 0.624; 95 % CI, 0.481-0.810; p = 0.0004) compared to patients with an ED cancer (Figs. 1, 2 ). Median TTFR in ED patients was achieved at 67 months compared to 25 months in TN patients (Figs. 1,  2) .
To evaluate the impact of therapy on tumor natural history, data were further analyzed first in patients receiving adjuvant therapy and next in systemically untreated women (Table 5 ). In the adjuvant (chemo, endo (Figs. 3, 4) . This is not surprising given the wide use of endocrine therapy in the ED group. In contrast, no TN triple negative, ED estrogen driven, TTFR time to first recurrence, OS overall survival, OR odds ratio statistical significant difference in TTFR or OS was observed in patients not receiving any systemic adjuvant therapy (Figs. 5, 6 ). Among TN patients only, regardless of the treatment, at univariable analyses EGFR expression, aneuploidy or higher proliferation were not significantly associated to worse outcome.
Multivariable analyses
The role of TN subtype as a prognostic factor on TTFR and OS was further evaluated by multivariable analyses in all subjects and by treatment group (Table 5 ). Potential confounders included in the model were tumor size, nodal status and S-phase. In untreated patients, TN was not associated with TTFR and OS. However, in patients treated with systemic adjuvant therapy, TN subtype was independently associated with worse TTFR (OR, 0.619; 95 % CI, 0.385-0.997; p = 0.0485) and OS (OR, 0.596; 95 % CI, 0.380-0.936; p = 0.0244).
In order to define the prognostic value of EGFR, ploidy, and proliferation rate in patients with TN tumors, multivariate analyses were performed. Potential confounders included in the model were tumor size, nodal status, and S-phase. Surprisingly, neither EGFR status nor aneuploidy was associated with outcome in this group of women.
Discussion
Targeted therapy has changed the natural history of BC expressing either ER, PgR and/or HER2. Unfortunately, there is a 10-15 % of BC not expressing either of these targets. For these tumors, often referred as TN, chemotherapy remains the only therapeutic tool. TN tumors are commonly believed to be more aggressive and related to a worse survival compared to non-TN tumors [19] .
In this study we have analyzed a well-characterized database comprising BC patients with extensive data regarding tumor biology, treatment information and outcomes. We compared two cohorts of patients using very stringent clinical characteristics to limit confounding factors. Therefore, ED tumors were defined as ER and PgR positive excluding ER negative/PgR positive and ER positive/PgR negative patients who carry a more aggressive, less sensitive to hormonal treatment phenotype [20] . For the same reasons, all patients expressing HER2 were excluded from the ED group. On the other hand, the TN cohort is defined by the lack of ER, PgR, and HER2 expression similarly to the routine clinical practice of medical oncologists worldwide [21] .
We show that TN tumors are larger, more proliferative and more aneuploid compared to ED tumors. We also confirm previous data in the literature of TN tumors being more frequent in young, African-American patients compared to non-TN tumors [22, 23] . Not surprisingly, when we studied TN tumors according to either ploidy or proliferative status, we found that TN tumors displaying higher aneuploidy or proliferation show also a more aggressive biology.
Several studies have investigated the role of EGFR as predictive or prognostic factor in BC [24] [25] [26] [27] [28] [29] . We have recently shown that, EGFR expression, more common in BC of younger and black women, is associated with lower hormone receptor levels, higher proliferation, genomic instability, and HER2 overexpression [30] . In the same paper, EGFR status is correlated with higher risk of relapse in patients receiving adjuvant treatment despite tumor histotypes and ER, PgR, and HER2 levels.
Upon looking further into the TN EGFR?group, we also found that among TN patients, those with EGFR positivity display a distinct, biologically more aggressive phenotype. However, these features do not significantly affect long-term Fig. 6 Time to first recurrence by receptor group status in TN and ED untreated subjects survival. EGFR status, in particular, does not confer a worse prognosis to TN patients. In the light of recent data showing disappointing results for the anti-EGFR-specific antibody cetuximab in metastatic TN breast cancer treatment [31] , our data suggest that EGFR is not a strong biological determinant of TN tumor biology, at least not at this discrete time point in the evolution of BC. Our data are in contrast with other findings showing that EGFR-positive basal-like tumors have a poorer prognosis compared to EGFR-negative tumors [32] . This might be in part explained by the different method used for EGFR evaluation in our work and by the different criteria used for allocating patients to sub-groups (basal-/non-basallike vs. TN/ED in our work).
Tumor ploidy is a surrogate marker of genomic instability [33] . We show in this work that TN tumors, compared to non-TN tumors are more frequently aneuploid. Therefore, TN tumors might be more sensitive to agents targeting genomic instability such as anti-DNA repair targeted agents.
Recent data have shown that TN tumors are a heterogeneous group of diseases that differ substantially in terms of outcome and response to treatment [34] . We were not able to find in our database any independent determinant of such heterogeneity since all of the analyzed factors did not significantly affect survival in multivariate analysis. This is suggestive of a complex biology underlying such heterogeneity requiring detailed molecular analyses to be dissected.
Most of the available data in the literature about the prognostic value of the TN phenotype are based on analyses of patients populations that are largely chemo and/or hormonal treated [8, 32, [35] [36] [37] [38] [39] . Since TN patients do not receive treatments that are as effective as endocrine treatment for ED patients, this makes prognostic conclusions not easily dissectible from treatment response predictions. The unique availability to our database of survival data for an untreated BC population fully characterized for ER/PgR and HER2 status gave us the possibility of exploring the true prognostic significance of the TN phenotype. Surprisingly, while in the chemo-and/or hormone-treated population the TN phenotype was significantly associated with a worse outcome compared to the ED group, such association was lost in the untreated population both at univariate and at multivariate analyses. This observation might be explained in two ways. First, the untreated population of patients in our data set has an excellent longterm prognosis both in the ED and in the TN subgroups. Therefore, a much larger sample size would be required to show a significant difference in outcome between such good prognostic cohorts. On the other hand, it is well known that both ER and PgR have very week prognostic value on long-term patient outcome [40] , therefore we cannot exclude that, in the absence of an efficacious targeted treatment such as endocrine therapy, ED tumors would behave similarly to TN tumors for which no specific treatment exists to date. If this hypothesis is true, TN and ED tumors would not differ in their natural history but mostly in their exquisite sensitivity to a specific targeted agent. On this regard, it has been recently shown that HER2-positive patients, who are known to have a poor prognosis in the absence of treatment compared to HER2 negative patients, when treated with the HER2-specific monoclonal antibody trastuzumab achieve a similar survival as compared to HER2 negative patients [41] .
In conclusion, our work displays an analysis of a unique, large database with well-characterized tumors and patients information that largely confirms data which are already been reported in the literature and gives novel and surprising view-angles for the interpretation of the TN phenotype in BC.
